Urologia Internationalis
Original Paper
Role of MMP-1 1G/2G Promoter Gene Polymorphism on the Development of Prostate Cancer in the Turkish PopulationAlbayrak S.a · Cangüven Ö.a · Göktaş C.a · Aydemir H.a · Köksal V.baClinic of Second Urology, Kartal Training Hospital, Istanbul, and bBurc Molecular Genetic Diagnosis and Research Laboratory, Istanbul, Turkey
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: November 24, 2005
Accepted: December 04, 2006
Published online: November 22, 2007
Issue release date: November 2007
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 2
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Abstract
Introduction: To investigate the association of 1G/2G polymorphism in matrix metalloproteinase-1 (MMP-1) promoter with susceptibility to prostate carcinoma in the Turkish population. Materials and Methods: MMP-1 promoter polymorphism was genotyped by PCR-RFLP analysis in 55 prostate cancer patients and 43 healthy controls. Results: The frequency of 1G/2G genotypes in prostate cancer patients was similar to that of the controls (all p values were >0.05). Compared with the 1G/1G genotype, neither the 2G/2G nor a combination with the 1G/2G genotype significantly modified the risk of developing prostate cancer and metastasis status. In addition, the frequencies of genotypes were not significantly different among patients stratified by smoking status and family history of prostate cancer. Conclusions: The 2G allele of the MMP-1 promoter polymorphism might not modify the risk of prostate cancer development and might not be used as a putative marker to predict the potential of metastasis in this cancer type, at least in the Turkish population.
© 2007 S. Karger AG, Basel
Related Articles:
References
- Brinckerhoff CE, Rutter JL, Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823–4830.
- Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321–5325.
- Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer 2003;106:372–374.
-
Hirata H, Naoko O, Katsusuke N, Ryo I, Satoru Y: Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP3 polymorphisms with renal cell carcinoma. Carcinogenesis 2004;12:2379–2384.
External Resources
- Zhu Y, Spitz MR, Lei L, Mills GB, Wu X: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001;61:7825–7829.
- Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, Hazama S, Kitamura Y, Kamatani N, Oka M: Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer 2002;102:526–529.
- Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM, Day I, Howell WM: Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase-1 gene polymorphism. Cancer Res 2001;61:1296–1298.
- Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, Terakawa N, Nakamura Y: Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999;59:4225–4227.
- Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R: A relationship between matrix metalloproteinase-1 promoter polymorphism and cervical cancer progression. Cancer Lett 2003;200:49–55.
- Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, Scorza R: Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7:2344–2346.
- D’Armiento J, Di Colandrea T, Dalal SS, Okada Y, Huang MT, Conney AH, Chada K: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 1995;15:5732–5739.
- Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE: Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791–797.
- Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR: Distribution of collagenase and tissue inhibitor of metalloproteinases in colorectal tumours. Int J Cancer 1991;49:666–672.
- Templeton NS, Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG: Cloning and characterization of human tumor cell interstitial collagenase. Cancer Res 1990;50:5431–5437.
- Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461–462.
- Murray GI, Duncan ME, O’Neil P, McKay JA, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256–261.
- Lukashev ME, Werb Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 1998;8:437–441.
- Singer CF, Marbaix E, Kokorine I, Lemoine P, Donnez J, Eeckhout Y, Courtoy PJ: Paracrine stimulation of interstitial collagenase (MMP-1) in the human endometrium by interleukin-1α and its dual block by ovarian steroids. Proc Natl Acad Sci USA 1997;94:10341–10345.
- Wyatt CA, Coon CI, Gibson JJ, Brinckerhoff CE: Potential for the 2G single nucleotide polymorphism in the promoter of matrix metalloproteinase to enhance gene expression in normal stromal cells. Cancer Res 2002;62:7200–7202.
Article / Publication Details
Received: November 24, 2005
Accepted: December 04, 2006
Published online: November 22, 2007
Issue release date: November 2007
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 2
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
